TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Maze Therapeutics announced that CEO Jason Coloma will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The clinical-stage biopharmaceutical company is developing small molecule precision medicines for kidney and metabolic diseases, with lead programs MZE829 (Phase 2 for APOL1-mediated kidney disease) and MZE782 (advancing to Phase 2 for PKU and chronic kidney disease).

Insights
CYTK   neutral

Mentioned only in passing with no specific details about company performance


MAZE   positive

The company is advancing its pipeline programs to Phase 2 development and securing a presentation slot at a major industry conference, indicating progress in drug development and investor engagement. The announcement highlights clinical advancement of lead candidates for significant disease indications.